* This work was supported by NIH research Grant
no., CA 11426 from the National Cancer Institute
A. Summary
The structural hallmark of retroviral transforming onc genes is
a specific RN A sequence that is unrelated to the essential retroviral
genes but closely related to certain cellular prototypes termed
proto-onc genes. Two types of onc genes have been distinguished.
Type I are onc genes which utilize elements of specific sequences
only to encode a transforming protein. Type II onc genes are hybrids
which utilize essential viral (typically gag) and specific RNA sequences
to encode transforming proteins. Comparisons between viral onc genes
and cellular proto-onc genes are reviewed in the light of two competing
models for protoonc function: the quantitative model, which holds
that viral onc genes and cellular proto-onc genes are functionally
the same and that transformation is the result of enhanced dosage
of a cellular proto-onc gene; and the qualitative model, which holds
that they are different. Structural comparisons between viral onc
genes and cellular prototypes have demonstrated extensive sequence
homologies in the primary structures of the specific sequences.
However, qualitative differences exist in the structure and organization
of viral onc genes and cellular prototypes. These include differences
in promoters, minor differences in the primary structure of shared
sequences, and absolute differences such as in the presence of sequences
which are unique to viral onc genes or to corresponding cellular
genetic units. For example, type II hybrid onc genes of retroviruses
share only their specific but not their gag-related elements with
the cell, and cellular proto-onc genes are interrupted by sequences
of nonhomology relative to viral onc genes.
In addition, proto-onc gene units may include unique cellular coding
sequences not shared with viral onc genes. There is circumstantial
evidence that some proto-onc genes are potentially oncogenic after
activation ( quantitative model) or modification ( qualitative model).
Activated by an adjacently integrated retroviral promotor, the cellular
prototype of the onc gene of the avian acute leukemia virus MC29
was proposed to cause lymphoma and activated by ligation with viral
promoter sequences two proto-onc DNAs, those of Moloney and Harvey
sarcoma viruses, were found to transform mouse 3T3 cell lines. Mutations
presumably conferred 3T3 cell-transforming ability to the proto-onc
gene of Harvey sarcoma virus that has been isolated from a human
bladder carcinoma cell line. In no case has an unaltered proto-onc
as yet been shown to be necessary and sufficient for carcinogenesis.
Despite this and structural differences between viral onc genes
and cellular proto-onc genes, we cannot at present conclusively
distinguish between the quantitative and the qualitative models
because agenetic and functional definition of most viral onc genes
and of all cellular prototypes of viral onc genes are not as yet
available.
|